ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ImmunityBio, Inc.NASDAQ: IBRX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $52.49M rose 59.9% year over year, ahead of the +24.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +12.7% a year.
Context
- Selling, general & admin amounted to 129.9% of revenue in FY2025, down 1014.8 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $31.89B (+21570.4%) for the fiscal year ending Dec 2026, a step up from the -12.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $52.49M+3.7% QoQ
- Last fiscal yearDec 2025
- $147.18M-12.8% YoY
- LTMSep 2026
- $185.41M+24.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 147.18M USD
- Year-over-year change
- -12.8%
- 4-year CAGR
- +2.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 147.18M | -12.8% |
| FY2024 | 2024-12-31 | 168.78M | +30.2% |
| FY2023 | 2023-12-31 | 129.62M | +26.2% |
| FY2022 | 2022-12-31 | 102.71M | -24.1% |
| FY2021 | 2021-12-31 | 135.26M | — |
Selling, General & Admin vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.0% is the 2nd highest of 10, against a peer median of -3.4%.
- Selling, general & admin amounts to 101.6% of revenue for IBRX, versus a peer median of 39.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $979M USD | -7.7% | -3.5% | 38.8% | |
| LTM Jun 2026 | €788.8M EUR | +45.9% | +8.9% | 29.8% | |
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Sep 2026 | $185.41M USD | +24.0% | +12.7% | 101.6% | |
| LTM Sep 2026 | $153.2M USD | -3.3% | +13.5% | 40.4% | |
| LTM Mar 2026 | $151.41M USD | -3.4% | — | 39.2% | |
| LTM Mar 2026 | $69.19M USD | — | — | 105.6% | |
| LTM Mar 2026 | $55.88M USD | -11.2% | -10.5% | — | |
| LTM Mar 2026 | €53.63M EUR | +14.4% | +12.3% | 143.8% | |
| LTM Mar 2026 | $25.06M USD | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $17.8M USD | -55.8% | -27.2% | 76.9% | |
| Peer median (excluding IBRX) | — | -3.4% | +6.4% | 39.8% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 934K | 240K | 622K | 14.75M | 113.29M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 753K |
| Gross Profit | 934K | 240K | 622K | 14.75M | 112.54M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| Research & Development | 195.96M | 248.15M | 232.37M | 190.14M | 207.88M |
| Selling, General & Admin | 135.26M | 102.71M | 129.62M | 168.78M | 147.18M |
| Operating Expenses | 331.21M | 351.54M | 362.87M | 358.93M | 368.56M |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| EBITDA | (320.75M) | (351.88M) | (478.66M) | (264.43M) | (223.56M) |
| EBITDA Margin | -34341.8% | -146617.1% | -76955.5% | -1793.4% | -197.3% |
| Operating Income | (330.28M) | (351.3M) | (362.25M) | (344.18M) | (256.03M) |
| Operating Margin | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Interest Income | 836K | 2.71M | 863K | 2.4M | 6.7M |
| Interest Expense | 14.85M | 47.15M | 86.72M | 131.66M | 112.53M |
| Other Income / Expenses | (19.56M) | (65.99M) | (221.64M) | (69.46M) | (95.58M) |
| Income Before Tax | (349.84M) | (417.29M) | (583.89M) | (413.65M) | (351.61M) |
| Pre-Tax Margin | -37456.0% | -173869.2% | -93873.3% | -2805.3% | -310.4% |
| Income Tax Expense | 9K | 34K | (40K) | 0 | (135K) |
| Net Income | (346.79M) | (416.57M) | (583.2M) | (413.56M) | (351.4M) |
| Net Margin | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (Basic) | (0.89) | (1.04) | (1.15) | (0.59) | (0.38) |
| EPS (Diluted) | (0.89) | (1.04) | (1.15) | (0.62) | (0.38) |
| Weighted Avg Shares | 389.23M | 399.9M | 508.64M | 697.31M | 919.86M |
| Weighted Avg Shares (Diluted) | 389.23M | 399.9M | 508.64M | 700.44M | 919.86M |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.